Key issues in phage therapy: A report of a dedicated workshop at the viruses of microbes II meeting

Research in Microbiology

Volumn 164, Issue 7, 2013, Pages 806-810

  Huys, Isabelle ^a   Vaneechoutte, Mario ^b   Verbeken, Gilbert ^c   Debarbieux, Laurent ^d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^d INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM MUTANT; CLINICAL TRIAL (TOPIC); EDITORIAL; EXPERT SYSTEM; HEALTH CARE COST; IMMUNITY; INFECTION; NON PROFIT ORGANIZATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VIROTHERAPY; WELLBEING; WORKSHOP;

EID: 84881552836     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2013.03.020     Document Type: Editorial

References (16)

1. Brüttin A., Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 2005, 49:2874-2878.
2. Brüssow H. What is needed for phage therapy to become a reality in Western medicine?. Virology 2012, pii: S0042-6822(12)00456-4. 10.1016/j.virol.2012.09.015.
3. Chanishvili N. A Literature Review of the Practical Application of Bacteriophage Research 2009, 184. Eliava Institute of Bacteriophage, Microbiology & Virology, Tbilisi, Georgia.
4. Chanishvili N. Phage therapy - history from Twort and d'Herelle through Soviet experience to current approaches. Adv. Virus Res. 2012, 83:3-40.
5. Comeau A.M., Tétart F., Trojet S.N., Prère M.-F., Krisch H.M. Phage-antibiotic synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2007, 2(8):e799.
6. Górski A., Miedzybrodzki R., Borysowski J., Weber-Dabrowska B., Lobocka M., Fortuna W., Letkiewicz S., Zimecki M., Filby G. Bacteriophage therapy for the treatment of infections. Curr. Opin. Investig. Drugs 2009, 10:766-774.
7. Górski A., Miedzybrodzki R., Borysowski J., Dabrowska K., Wierzbicki P., Ohams M., Korczak-Kowalska G., Olszowska-Zaremba N., Lusiak-Szelachowska M., Kłak M., Jończyk E., Kaniuga E., Gołaś A., Purchla S., Weber-Dabrowska B., Letkiewicz S., Fortuna W., Szufnarowski K., Pawełczyk Z., Rogóz P., Kłosowska D. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 2012, 83:41-71.
8. Hall A.R., De Vos D., Friman V.P., Pirnay J.P., Buckling A. Effects of sequential and simultaneous application of bacteriophages on populations of Pseudomonas aeruginosa invitro and in waxmoth larvae. Appl. Environ. Microbiol. 2012 Jun 1, (Epub ahead of print).
9. PHAGESPOIR. http://phagespoirs.unblog.fr/.
10. P.H.A.G.E.: Phage for Human Application Group Europe. http://www.p-h-a-g-e.org.
11. Pirnay J.P., De Vos D., Verbeken G., Merabishvili M., Chanishvili N., Vaneechoutte M., Zizi M., Laire G., Lavigne R., Huys I., Van den Mooter G., Buckling A., Debarbieux L., Pouillot F., Azeredo J., Kutter E., Dublanchet A., Górski A., Adamia R. The phage therapy paradigm: Prêt-à-porter or sur-mesure?. Pharm. Res. 2011, 28:934-937.
12. Pirnay J.P., Verbeken G., Rose T., Jennes S., Zizi M., Huys I., Lavigne R., Merabishvili M., Vaneechoutte M., Buckling A., De Vos D. Introducing yesterday's phage therapy in today's medicine. Future Virol. 2012, 7(4):379-390.
13. Smith H.W., Huggins M.B. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 1982, 128:307-318.
14. Verbeken G., De Vos D., Vaneechoutte M., Merabishvili M., Zizi M., Pirnay J.P. European regulatory conundrum of phage therapy. Future Microbiol. 2007, 2:485-491.
15. Weber-Dabrowska B., Mulczyk M., Górski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch. Immunol. Ther. Exp. 2000, 48:547-551.
16. Wright A., Hawkins C.H., Anggård E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009, 34:349-357.